Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.
Constantinescu CS, Asher A, Fryze W, Kozubski W, Wagner F, Aram J, Tanasescu R, Korolkiewicz RP, Dirnberger-Hertweck M, Steidl S, Libretto SE, Sprenger T, Radue EW. Constantinescu CS, et al. Among authors: wagner f. Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e117. doi: 10.1212/NXI.0000000000000117. eCollection 2015 Aug. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26185773 Free PMC article.
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ. Tillner J, et al. Among authors: wagner m, wagner f. Diabetes Obes Metab. 2019 Jan;21(1):120-128. doi: 10.1111/dom.13494. Epub 2018 Sep 16. Diabetes Obes Metab. 2019. PMID: 30091218 Clinical Trial.
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ. Dörner T, et al. Ann Rheum Dis. 2019 May;78(5):641-647. doi: 10.1136/annrheumdis-2018-214720. Epub 2019 Mar 2. Ann Rheum Dis. 2019. PMID: 30826774 Clinical Trial.
Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study.
Kucher K, Johns D, Wagner F, Abd-Elaziz K, Derne C, Sverdlov O, Pfister CU, Langguth B. Kucher K, et al. Among authors: wagner f. Prog Brain Res. 2021;260:423-440. doi: 10.1016/bs.pbr.2020.12.004. Epub 2021 Jan 20. Prog Brain Res. 2021. PMID: 33637230 Clinical Trial.
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN, Wagner F, Hüser A, Igel J, Joseph D, Hilbert J, Schoelch C, Padula SJ, Steffgen J. Albach FN, et al. Among authors: wagner f. Eur J Clin Pharmacol. 2018 Feb;74(2):161-169. doi: 10.1007/s00228-017-2362-8. Epub 2017 Nov 10. Eur J Clin Pharmacol. 2018. PMID: 29127458 Free PMC article. Clinical Trial.
1,648 results